For yderligere information om fortsat behandling med oral olanzapin (5 til 20 mg daglig) henvises til produktresuméet for ZYPREXA overtrukne tabletter eller ZYPREXA VELOTAB smeltetabletter.
For further information on continued treatment with oral olanzapine (5 to 20 mg daily), see the Summary of Product Characteristics for ZYPREXA coated tablets or ZYPREXA VELOTAB orodispersible tablets.